José Luis Blanco´s group
null José Luis Blanco´s group
Resistance to antiretrovirals, STI's and Papilomavirus in HIV patients
Our research group have been working in this field for the last years focused in three topics of HIV research:
- Resistance to antiretrovirals (for the last 12 years)
- Sexually transmitted Infections (STI) (for the last 5 years)
- Human Papilomavirus (HPV) (for the last 3 years)
The resistance to antiretroviral drugs could be both a cause and consequence of virological failure and it is therefore, one of the main topics of HIV therapy. Although Human Papilomavirus (HPV) infection is in fact another STI, it is considerated as another different topic due to, its exceptional prevalence in HIV infected individuals (mainly MSM) and, its role in the development of anal cancer.
Resistance to antiretrovirals
Our group has been and is involved in several trials that assess the role of the resistance to antiretrovirals drugs in the antiretroviral therapy efficacy. Our main research has been focused on genotype-clinical associations in which the clinical significance of drug resistance mutations are correlated with the virological response to a subsequent antiretroviral treatment regimen while controlling for other variables that influence clinical response. We have been involved as well in other pillars of antiviral drug resistance knowledge as genotype-phenotype associations, in many narrow colaborations with other agencies and groups (i.e. RIS or Stanford HIV Drug Resistance Database).
Sexually Transmitted Diseases
Our group has been also involved in the epidemiology, prevention and management of STI’s since these events gained increasing importance a few years ago. Together with other clinical research groups ( AIDS Study Group/Spanish AIDS Plan) we have been involved in developing prevention and management guidelines on sexually transmitted infections in HIV-infected patients. We are collaborating with other public agencies (CESCAT) and research groups (Microbiology Department Hospital Vall d’Hebron) in the epidemiology and patterns of resistance of different STI’s.
Human Papilomavirus infection
Our group is one of the first in Spain involved in the epidemiology, prevention and management of anal cancer related with the HPV in HIV+ infected people. Our team is working in some projects with other research groups: Institut Català d’Oncologia (ICO), HIVACAT and Hospital Vall d’Hebron.